Another interesting article (for a number of reasons) surrounding the current climate of the US pharma market/FDA approval pathway, specifically GlaxoSmithKline's new myeloma fighting drug."The US Food and Drug Administration (FDA) has fast-tracked GSK’s antibody-drug conjugate (ADC) belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma. GSK filed the drug back inDecemberafter the drug demonstrated positive results in clinical trials.
The priority review was based on the positive results from a second pivotal trial of the ADC –DREAMM2 – which revealed a 31% overall response rate (ORR) for those receiving the drug who had exhausted multiple previous treatment options for multiple myeloma."
Underlined for effect. Sounds pretty familiar...
Edit: Forgot the link: https://www.pmlive.com/pharma_news/fda_fast-tracks_gsks_anti-bcma_drug_for_multiple_myeloma_1323112
General Comments / Chat, page-50
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |